메뉴 건너뛰기




Volumn 6, Issue SUPPL. 2, 2000, Pages

Hodgkin's disease

Author keywords

Biology; Chemotherapy; High dose chemotherapy; Hodgkin's disease; Prognostic factors; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

EID: 0033928177     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (19)

References (43)
  • 1
    • 0000295746 scopus 로고
    • Cases of sarcoma and Hodgkin's disease treated by exposure to X-rays: A preliminary report
    • Pusey WA. Cases of sarcoma and Hodgkin's disease treated by exposure to X-rays: a preliminary report. JAMA 1902;38:166-169.
    • (1902) JAMA , vol.38 , pp. 166-169
    • Pusey, W.A.1
  • 2
    • 0001613360 scopus 로고
    • Therapeutical value of roentgen ray in treatment of pseudoleukemia
    • Senn N. Therapeutical value of roentgen ray in treatment of pseudoleukemia. New York Med J 1903;77:665-668.
    • (1903) New York Med J , vol.77 , pp. 665-668
    • Senn, N.1
  • 3
    • 0018822166 scopus 로고
    • Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP-treated patients at the National Cancer Institute
    • DeVita VT Jr, Simon RM, Hubbard G et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-595.
    • (1980) Ann Intern Med , vol.92 , pp. 587-595
    • DeVita V.T., Jr.1    Simon, R.M.2    Hubbard, G.3
  • 4
    • 0016707139 scopus 로고
    • Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
    • Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-260.
    • (1975) Cancer , vol.36 , pp. 252-260
    • Bonadonna, G.1    Zucali, R.2    Monfardini, S.3
  • 5
    • 0004270741 scopus 로고
    • Cambridge: Harvard University Press
    • Kaplan H. Hodgkin's disease. Cambridge: Harvard University Press, 1980:2.
    • (1980) Hodgkin's Disease , pp. 2
    • Kaplan, H.1
  • 6
    • 0027315157 scopus 로고
    • Recent results on the biology of Hodgkin and Reed-Sternberg cells II: Continuous cell lines
    • Drexler H. Recent results on the biology of Hodgkin and Reed-Sternberg cells II: continuous cell lines. Leuk Lymphoma 1993;9:1-24.
    • (1993) Leuk Lymphoma , vol.9 , pp. 1-24
    • Drexler, H.1
  • 7
    • 0027935346 scopus 로고
    • The cellular biology of the Reed-Sternberg cell
    • Haluska FG, Brufsky AM, Canellos GP et al. The cellular biology of the Reed-Sternberg cell. Blood 1994;84:1005-1015.
    • (1994) Blood , vol.84 , pp. 1005-1015
    • Haluska, F.G.1    Brufsky, A.M.2    Canellos, G.P.3
  • 8
    • 0031919997 scopus 로고    scopus 로고
    • The origin of Hodgkin and Reed-Sternberg cells
    • Küppers R, Rajewsky K. The origin of Hodgkin and Reed-Sternberg cells. Annu Rev Immunol 1998;16:471-479.
    • (1998) Annu Rev Immunol , vol.16 , pp. 471-479
    • Küppers, R.1    Rajewsky, K.2
  • 9
    • 0029952779 scopus 로고    scopus 로고
    • Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
    • Kanzler H, Küppers R, Hansmann ML et al: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-1505.
    • (1996) J Exp Med , vol.184 , pp. 1495-1505
    • Kanzler, H.1    Küppers, R.2    Hansmann, M.L.3
  • 10
    • 0030834265 scopus 로고    scopus 로고
    • Hodgkin Reed-Sternberg cells in lymphocyte predominant Hodgkin's disease represent clonal population of germinal center-derived tumor cells
    • Braeuninger A, Küppers R, Strickler JG et al: Hodgkin Reed-Sternberg cells in lymphocyte predominant Hodgkin's disease represent clonal population of germinal center-derived tumor cells. Proc Natl Acad Sci 1997;94:9337-9342.
    • (1997) Proc Natl Acad Sci , vol.94 , pp. 9337-9342
    • Braeuninger, A.1    Küppers, R.2    Strickler, J.G.3
  • 12
    • 0023849566 scopus 로고
    • Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors
    • Carde P, Burger JM, Henry-Amar M. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-248.
    • (1988) J Clin Oncol , vol.6 , pp. 239-248
    • Carde, P.1    Burger, J.M.2    Henry-Amar, M.3
  • 13
    • 0024796020 scopus 로고
    • Risk factor adapted treatment of Hodgkin's lymphoma: Strategies and perspectives. Recent Results
    • Loeffler M, Pfreundschuh M, Rühl U. Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives. Recent Results. Cancer Res 1989;117:142.
    • (1989) Cancer Res , vol.117 , pp. 142
    • Loeffler, M.1    Pfreundschuh, M.2    Rühl, U.3
  • 14
    • 0032548107 scopus 로고    scopus 로고
    • A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
    • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.
    • (1998) N Engl J Med , vol.339 , pp. 1506
    • Hasenclever, D.1    Diehl, V.2
  • 15
    • 0005397035 scopus 로고    scopus 로고
    • Final results of a randomized trial (HD4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin's disease PS I/II
    • Rüffer U, Sieber M, Tesch H. Final results of a randomized trial (HD4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin's disease PS I/II. Blood 1997;90(suppl):143.
    • (1997) Blood , vol.90 , Issue.SUPPL. , pp. 143
    • Rüffer, U.1    Sieber, M.2    Tesch, H.3
  • 17
    • 0001258960 scopus 로고    scopus 로고
    • Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: Interim analysis of the HD8 trial (GHSG)
    • Rüffer U, Sieber M, Pfistner B et al. Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: interim analysis of the HD8 trial (GHSG). Ann Oncol 1999;10(suppl 3):250.
    • (1999) Ann Oncol , vol.10 , Issue.SUPPL. 3 , pp. 250
    • Rüffer, U.1    Sieber, M.2    Pfistner, B.3
  • 18
    • 0026439199 scopus 로고
    • Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
    • Canellos GP, Anderson JR, Propert KJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1485.
    • (1992) N Engl J Med , vol.327 , pp. 1478-1485
    • Canellos, G.P.1    Anderson, J.R.2    Propert, K.J.3
  • 19
    • 8244252294 scopus 로고    scopus 로고
    • Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group
    • Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:1638-1645.
    • (1997) J Clin Oncol , vol.15 , pp. 1638-1645
    • Connors, J.M.1    Klimo, P.2    Adams, G.3
  • 20
    • 0021075273 scopus 로고
    • A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy
    • Carde P, MacKintosh F, Rosenberg S. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983;1:146-153.
    • (1983) J Clin Oncol , vol.1 , pp. 146-153
    • Carde, P.1    MacKintosh, F.2    Rosenberg, S.3
  • 21
    • 0028988635 scopus 로고
    • Brief chemotherapy, Stanfotd V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
    • Bartlett N, Rosenberg S, Hoppe R et al. Brief chemotherapy, Stanfotd V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-1089.
    • (1995) J Clin Oncol , vol.13 , pp. 1080-1089
    • Bartlett, N.1    Rosenberg, S.2    Hoppe, R.3
  • 22
    • 0032422646 scopus 로고    scopus 로고
    • BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
    • Diehl V, Franklin J, Hasenclever D et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16:3810-3819.
    • (1998) J Clin Oncol , vol.16 , pp. 3810-3819
    • Diehl, V.1    Franklin, J.2    Hasenclever, D.3
  • 23
    • 0031887688 scopus 로고    scopus 로고
    • Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group
    • Loeffler M, Brosteanu O, Hasenclever D et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group J Clin Oncol 1998;16:818.
    • (1998) J Clin Oncol , vol.16 , pp. 818
    • Loeffler, M.1    Brosteanu, O.2    Hasenclever, D.3
  • 24
    • 0015399024 scopus 로고
    • Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
    • Cannellos G, Young RC, DeVita VD. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972;13:750-758.
    • (1972) Clin Pharm Ther , vol.13 , pp. 750-758
    • Cannellos, G.1    Young, R.C.2    DeVita, V.D.3
  • 25
    • 0022608592 scopus 로고
    • Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP
    • Santoro A, Viviani S, Villarreal C et al: Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986;70:343-351.
    • (1986) Cancer Treat Rep , vol.70 , pp. 343-351
    • Santoro, A.1    Viviani, S.2    Villarreal, C.3
  • 26
    • 0018744297 scopus 로고
    • Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse
    • Fisher R, De VV, Hubbard S et al: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Int Med 1979;90:761-768.
    • (1979) Ann Int Med , vol.90 , pp. 761-768
    • Fisher, R.1    De, V.V.2    Hubbard, S.3
  • 27
    • 0026558372 scopus 로고
    • Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
    • Longo D, Duffey P, Young R et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210-219.
    • (1992) J Clin Oncol , vol.10 , pp. 210-219
    • Longo, D.1    Duffey, P.2    Young, R.3
  • 28
    • 0022982371 scopus 로고
    • CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease
    • Santoro A, Viviani S, Valagussa P et al. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986;13:23-32.
    • (1986) Semin Oncol , vol.13 , pp. 23-32
    • Santoro, A.1    Viviani, S.2    Valagussa, P.3
  • 29
    • 0025608296 scopus 로고
    • Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: A CALGB study
    • Schulman P, McCarroll K, Cooper M et al. Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study. Med Ped Oncol 1990;18:482-490.
    • (1990) Med Ped Oncol , vol.18 , pp. 482-490
    • Schulman, P.1    McCarroll, K.2    Cooper, M.3
  • 30
    • 0028285134 scopus 로고
    • Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group
    • Pfreundschuh M, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994;12:580-592.
    • (1994) J Clin Oncol , vol.12 , pp. 580-592
    • Pfreundschuh, M.1    Rueffer, U.2    Lathan, B.3
  • 31
    • 0023267126 scopus 로고
    • MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
    • Hagemeister F, Tannir N, McLaughlin P et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1987;5:556-563
    • (1987) J Clin Oncol , vol.5 , pp. 556-563
    • Hagemeister, F.1    Tannir, N.2    McLaughlin, P.3
  • 32
    • 0033153007 scopus 로고    scopus 로고
    • ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease
    • Rodriguez J, Rodriguez M, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93:3632-3641.
    • (1999) Blood , vol.93 , pp. 3632-3641
    • Rodriguez, J.1    Rodriguez, M.2    Fayad, L.3
  • 33
    • 0023484082 scopus 로고
    • Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): A multi-center trial of the German Hodgkin's study group
    • Pfreundschuh MG, Schoppe WD, Fuchs R. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): a multi-center trial of the German Hodgkin's study group. Cancer Treatment Reports 1987;71:1203-1212.
    • (1987) Cancer Treatment Reports , vol.71 , pp. 1203-1212
    • Pfreundschuh, M.G.1    Schoppe, W.D.2    Fuchs, R.3
  • 34
    • 0028819356 scopus 로고
    • Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation
    • Cowill R, Crump M, Couture F. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-403.
    • (1995) J Clin Oncol , vol.13 , pp. 396-403
    • Cowill, R.1    Crump, M.2    Couture, F.3
  • 35
    • 0003345877 scopus 로고
    • Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin's disease
    • Velasquez WS, Jagannath S, Hagemeister FB. Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin's disease. Proc Am Soc Hematol 1986; 68:242-249.
    • (1986) Proc Am Soc Hematol , vol.68 , pp. 242-249
    • Velasquez, W.S.1    Jagannath, S.2    Hagemeister, F.B.3
  • 36
    • 0030710532 scopus 로고    scopus 로고
    • High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. (Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.)
    • Sweetenham J, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. (Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.) Bone Marrow Transplant 1997;20:745-751.
    • (1997) Bone Marrow Transplant , vol.20 , pp. 745-751
    • Sweetenham, J.1    Taghipour, G.2    Milligan, D.3
  • 37
    • 0027374883 scopus 로고
    • High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients
    • Bierman P, Bagin R, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993;4:767-774.
    • (1993) Ann Oncol , vol.4 , pp. 767-774
    • Bierman, P.1    Bagin, R.2    Jagannath, S.3
  • 38
    • 0025228997 scopus 로고
    • High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
    • Jones R, Piantadosi S, Mann R et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990;8:527-534.
    • (1990) J Clin Oncol , vol.8 , pp. 527-534
    • Jones, R.1    Piantadosi, S.2    Mann, R.3
  • 39
    • 0031967030 scopus 로고    scopus 로고
    • Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)
    • Josting A, Katay I, Rueffer U et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998;9:289-296.
    • (1998) Ann Oncol , vol.9 , pp. 289-296
    • Josting, A.1    Katay, I.2    Rueffer, U.3
  • 40
    • 0025945351 scopus 로고
    • Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease
    • Gianni A, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991;2:645-652.
    • (1991) Ann Oncol , vol.2 , pp. 645-652
    • Gianni, A.1    Siena, S.2    Bregni, M.3
  • 41
    • 0026329564 scopus 로고
    • Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
    • Armitage J, Bierman P, Vose J et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991;91:605-612.
    • (1991) Am J Med , vol.91 , pp. 605-612
    • Armitage, J.1    Bierman, P.2    Vose, J.3
  • 42
    • 0027404777 scopus 로고
    • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
    • Linch D, Winfield D, Goldstone A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051.
    • (1993) Lancet , vol.341 , pp. 1051
    • Linch, D.1    Winfield, D.2    Goldstone, A.3
  • 43
    • 0002992983 scopus 로고    scopus 로고
    • HDR-1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
    • Schmitz N, Sextro M, Pfistner B. HDR-1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 1999; 5(suppl): 18.
    • (1999) Proc Am Soc Clin Oncol , vol.5 , Issue.SUPPL. , pp. 18
    • Schmitz, N.1    Sextro, M.2    Pfistner, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.